The Molecular Profiling of Non-Small Cell Lung Cancer
Personalized therapies against lung cancer provide more efficient treatment options than conventional therapies, as they target the genetic makeup. Current treatment options are available against EGFR or ALK genes mutations. 667 cases of surgically resected lung cancer underwent molecular analysis for six possible gene mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK. The samples included different types of non-small-cell lung cancer. The highest mutation frequency was the KRAS mutation (24.4%) while the lowest was the HER2 mutation (0%). The significant correlations observed were: against age, where fewer older patients exhibited BRAF mutations; against gender, where females exhibited more EGFR mutations; against cell type, where adenocarcinoma exhibited more KRAS and EGFR mutations; against vascular invasion, where positive individuals had fewer EGFR mutations; against smoking history, where non-smokers exhibited more EGFR mutations. This study provides significant results for better understanding the gene mutation status and their significance in lung cancer patients.